The Elevated Employee Experience: Supporting Smarter Claims Recovery with Stephanie Wallace

At ElevatePFS, employees play a vital role in turning complex challenges into meaningful outcomes for clients and patients. Whether working behind the scenes or on the front lines of claims management, each individual contributes to the organization’s mission of delivering exceptional results.

Stephanie Wallace, a Workers’ Compensation Appeals Representative, supports that mission by reviewing EOBs, identifying underpayments, and submitting detailed appeals to ensure accurate reimbursement. Her work directly benefits both clients and injured workers by recovering payments that might otherwise be lost.

She values ElevatePFS for its supportive culture and the opportunity to make a tangible impact. Being part of a knowledgeable, purpose-driven team motivates her to bring her best to every claim.

Stephanie’s role is one example of how ElevatePFS fosters excellence across every stage of the revenue cycle.

Recent Episodes

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…